Has Robert Mayle, MD received payments from drug or device companies?

Yes. Drug and device makers reported $299,735 in general payments to Robert Mayle, MD across 185 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Robert Mayle, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Robert Mayle, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Robert Mayle, MD

Orthopaedic Surgery · Stanford, CANPI 1174710545

Payments from drug & device makers

$299,735in general payments, 2019–2025

Across 185 payments — averaging $1620.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medical Device Business Services, Inc.$284K
Depuy Synthes Products, Inc.$10K
Pacira Pharmaceuticals Incorporated$4K
Johnson & Johnson$1K
Heron Therapeutics, Inc.$38

What the payments were for

Consulting fees$280,17493%
Travel & lodging$16,6416%
Food & beverage$2,9201%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medical Device Business Services, Inc.	161	$284,150
Depuy Synthes Products, Inc.	6	$10,098
Pacira Pharmaceuticals Incorporated	4	$4,168
Johnson & Johnson(2 entities)	12	$1,282
Heron Therapeutics, Inc.	2	$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$299,735 in reported general payments places this provider in the 90th percentile of 1,808 orthopaedic surgery providers in California.

See all orthopaedic surgery providers in California →

Medicare billing

Part B allowed, 2024

$861,932

Medicare patients

1,075

Services billed

19,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Celecoxib	25	$2,249
Diclofenac Sodium	18	$309
Meloxicam	29	$230
Gabapentin	19	$108
Oxycodone Hcl	16	$97
Tramadol Hcl	18	$60

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Stanford

Ariel PalancaStanford$633K
Bradford HackArcadia$18.3M
Robert GorabOrange$14.5M
Kelly VinceLos Angeles$9.6M
Stephen HowellSacramento$9.4M
Thomas CoonRed Bluff$9.2M
Peter NewtonSan Diego$7M
Nirav AminPlacentia$5.8M
Tom NorrisSan Francisco$5.3M
Jay LiebermanLos Angeles$4.8M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →